Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR
| العنوان: | Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR |
|---|---|
| المؤلفون: | J Fris, Zhaolin Xu, Gordon Flowerdew, Wenda L. Greer, Paola Marcato, Mathieu Castonguay, Drew Bethune, Akram Alwithenani, Paola A. Marignani, Daniel French, Mary MacNeil, Wojciech Morzycki, Madelaine Plourde, Harry Henteleff, Stephanie Snow, Marika Forsythe, Arik Drucker |
| المصدر: | PLoS ONE PLoS ONE, Vol 16, Iss 5, p e0251080 (2021) |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Male, Lung Neoplasms, Cancer Treatment, Gene mutation, medicine.disease_cause, B7-H1 Antigen, Lung and Intrathoracic Tumors, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Medicine and Health Sciences, Medicine, Aged, 80 and over, Mutation, Multidisciplinary, Insertion Mutation, biology, Middle Aged, 3. Good health, ErbB Receptors, Oncology, 030220 oncology & carcinogenesis, Adenocarcinoma, Female, KRAS, Research Article, Adult, Science, Real-Time Polymerase Chain Reaction, Research and Analysis Methods, 03 medical and health sciences, PD-L1, ROS1, Genetics, Humans, Neoplasm Invasiveness, Lung cancer, Immunohistochemistry Techniques, Aged, business.industry, Carcinoma, Cancers and Neoplasms, Biology and Life Sciences, medicine.disease, Immune checkpoint, Non-Small Cell Lung Cancer, Histochemistry and Cytochemistry Techniques, 030104 developmental biology, Cancer research, biology.protein, Immunologic Techniques, Secondary Lung Tumors, business |
| الوصف: | Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options with very low response rate. Lung cancer is the most common cause of cancer death worldwide. Therapies that target driver gene mutations (e.g. EGFR, ALK, ROS1) and checkpoint inhibitors such anti-PD-1 and PD-L1 immunotherapies are being used to treat lung cancer patients. Identification of correlations between driver mutations and PD-L1 expression will allow for the best management of patient treatment. 851 cases of non-small cell lung cancer cases were profiled for the presence of biomarkers EGFR, KRAS, BRAF, and PIK3CA mutations by SNaPshot/sizing genotyping. Immunohistochemistry was used to identify the protein expression of ALK and PD-L1. Total PD-L1 mRNA expression (from unsorted tumor samples) was quantified by RT-qPCR in a sub-group of the cohort to assess its correlation with PD-L1 protein level in tumor cells. Statistical analysis revealed correlations between the presence of the mutations, PD-L1 expression, and the pathological data. Specifically, increased PD-L1 expression was associated with wildtype EGFR and vascular invasion, and total PD-L1 mRNA levels correlated weakly with protein expression on tumor cells. These data provide insights into driver gene mutations and immune checkpoint status in relation to lung cancer subtypes and suggest that RT-qPCR is useful for assessing PD-L1 levels. |
| تدمد: | 1932-6203 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44f87641d4daeb7b48aef39908cf0fddTest https://pubmed.ncbi.nlm.nih.gov/33956842Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....44f87641d4daeb7b48aef39908cf0fdd |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19326203 |
|---|